Cereno Scientific Is A Clinical Stage Biotechnology Company Based In Gothenburgswedenwith A U Ssubsidiary In Bostonmassachusettsthe Company Focuses On Developing Innovative Treatments For Rare Cardiovascular And Pulmonary Diseasesit Is Publicly Listed On Nasdaq First North Under The Ticker Crno B Cereno Specializes In Epigenetic Modulation And Disease Modifying Therapiesparticularly For Underserved Patient Populationsits Pipeline Includes Cs1A Histone Deacetylase Inhibitor In Phase Iia Development For Pulmonary Arterial Hypertensionpah And Cs014A Novel Hdaci In Phase I For Idiopathic Pulmonary Fibrosisipf Additionallycs585 Is A Preclinical Oral Prostacyclin Receptor Agonist Aimed At Thrombosis Prevention And Pulmonary Hypertensioncereno S Approach Emphasizes A Rare Disease First Strategyallowing For Efficient Clinical Development And Targeting High Unmet Medical Needsthe Company Operates Globallyconducting Clinical Trials And Collaborations Across Europe And The U S
United States
